ClinicalTrials.gg
Active, not recruitingNCT04421963ROSY-OUpdated Jun 12, 2026

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

A Phase 3 interventional study of Olaparib in Ovarian Cancer and Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 107 sites in 23 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
23rd of 69
185 · median 97
Started
2020
with 5 others
Phase 3
16 of 69
2 open now
Primary completion
2027-04
later than 15 of 25 live
Registered
47th of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 23rd largest by enrollment, is one of 6 that started in 2020, is one of 16 in phase 3, reaches primary completion later than 15 of the 25 other live ones, and was the 47th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

Read the detailed description

ROSY-O is an open label, non-randomised, multicentre,international trial for patients who have completed a parent study using olaparib and who are deriving clinical benefit from continued treatment as judged by the Investigator. Patients will be rolled-over from the parent study and will continue the study indefinitely, until they meet one of the treatment discontinuation criteria

03

Conditions studied

  • Ovarian Cancer
  • Breast Cancer

Keywords

  • HER2-ve metastatic
  • BRCA mutations
  • Cancer
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written ICF.
  2. Patient is currently deriving clinical benefit, as judged by the Investigator, from continued treatment in an AZ parent study using an AstraZeneca (AZ) compound that has met its endpoints or has otherwise stopped.
  3. Patient participating in a prior oncology study with an AZ compound in which they received olaparib and are continuing to receive clinical benefit from treatment; the prior study can be an open-label or blinded study, with unblinding at study close.

Exclusion criteria

Exclusion Criteria:

  1. Ongoing, unresolved, Grade 3 or above toxicity requiring interruption of treatment at the time of the termination of the parent study.
  2. Currently receiving treatment with any prohibited medication(s).
  3. Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  4. Permanent discontinuation from the parent study due to toxicity or disease progression.
  5. Local access to commercially-available drug at no cost to the patient is permitted by local regulation.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    Olaparib

    Treatment

    Drug: Olaparib

Interventions

  • 300 mg olaparib (2×150 mg tablets) twice daily

06

What researchers measure

Primary outcomes

  1. Safety follow up

    Serious adverse events and adverse events of special interest reported until 30 days after the last dose of study drug.

    Time frame: Baseline up to approximately 10 years

07

Study locations

107 sites
  • Research Site
    Boca Raton, Florida 33486, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Basking Ridge, New Jersey 07920, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Willow Grove, Pennsylvania 19090, United States
  • Research Site
    Providence, Rhode Island 02905, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Mississauga, Ontario L5M 2N1, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Montreal, Quebec H4A-3J1, Canada
  • Research Site
    Québec, Quebec G1S 4L8, Canada
  • Research Site
    Changchun, 130021, China
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Olomouc, 779 00, Czechia
  • Research Site
    Ostrava Poruba, 708 52, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Prague, 150 06, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Kuopio, 70210, Finland
  • Research Site
    Lille, 59020, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Plérin, 22190, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Dresden, 1307, Germany
  • Research Site
    Budapest, 1032, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Ramat Gan, 5265601, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Ancona, 60020, Italy
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Candiolo, 10060, Italy
  • Research Site
    Catania, 95126, Italy
  • Research Site
    Lecce, 73100, Italy
  • Research Site
    Lecco, 23900, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Torino, 10128, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Bialystok, 15-027, Poland
  • Research Site
    Grzepnica, 72-003, Poland
  • Research Site
    Lublin, 20-090, Poland
  • Research Site
    Olsztyn, 10-561, Poland
  • Research Site
    Poznan, 60-569, Poland
  • Research Site
    Poznan, 61-866, Poland
  • Research Site
    Lisbon, 1649-035, Portugal
  • Research Site
    Porto, 4200-072, Portugal
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Ljubljana, 1000, Slovenia
  • Research Site
    Seoul, 01812, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06273, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Seoul, 6351, South Korea
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 8907, Spain
  • Research Site
    Barcelona, ?08041, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Donostia / San Sebastian, 20014, Spain
  • Research Site
    Granada, 18014, Spain
  • Research Site
    Madrid, 28027, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Vigo, 36312, Spain
  • Research Site
    Zaragoza, 50009, Spain
  • Research Site
    Lund, 22185, Sweden
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Ankara, 06230, Turkey (Türkiye)
  • Research Site
    Istanbul, 34093, Turkey (Türkiye)
  • Research Site
    Şahinbey, 27310, Turkey (Türkiye)

Showing the first 100 of 107 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Apr 2027, 80 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 80 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2020
First posted
Jun 9, 2020
StartActual
Aug 4, 2020
Primary completionEst.
Apr 6, 2027
CompletionEst.
Apr 6, 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04421963
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Aug 4, 2020
Primary completion
Apr 6, 2027 (estimated)
Completion
Apr 6, 2027 (estimated)
Last update
Jun 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion